Related Experiment Videos
Serum soluble CD30 levels in Behçet's disease.
N Düzgün1, E Ayaslioglu, H Tutkak
1Ankara University, School of Medicine, Department of Clinical Immunology and Rheumatology, Turkey. duzgun@medicine.ankara.edu.tr
Clinical and Experimental Rheumatology
|November 2, 2004
Summary
Serum soluble CD30 (sCD30) levels are significantly elevated in active Behçet's disease patients, correlating with disease activity. This suggests sCD30 may indicate T-helper cell involvement in Behçet's disease pathogenesis.
Area of Science:
- Immunology
- Rheumatology
- Cellular Biology
Background:
- Behçet's disease (BD) involves inflammation, with CD4+ T helper 1 (Th1) cells implicated.
- Soluble CD30 (sCD30) is associated with CD4+ T helper 2 (Th2) cell activity.
- Understanding immune cell involvement is crucial for BD management.
Purpose of the Study:
- To investigate serum sCD30 levels in active and inactive Behçet's disease patients.
- To compare sCD30 levels with healthy controls and rheumatoid arthritis patients.
- To assess the correlation between sCD30 levels and clinical disease activity.
Main Methods:
- Serum samples from active BD, inactive BD, rheumatoid arthritis, and healthy control groups were analyzed.
- Enzyme immunoassay kits were used to quantify sCD30 levels.
- Clinical activity indices were assessed in active BD patients.
Main Results:
- Significantly higher mean sCD30 levels were observed in active BD patients compared to inactive BD patients, healthy controls, and RA patients.
- A significant correlation was found between elevated sCD30 levels and the clinical activity index in active BD patients.
- sCD30 levels were highest in active BD patients, suggesting a role in disease pathogenesis.
Conclusions:
- Elevated serum sCD30 levels are associated with active Behçet's disease.
- Increased sCD30 may reflect CD4+ T cell activation in active BD.
- Measuring sCD30 and Th2 cytokines could aid in evaluating Th2 activity in BD.